despit
recent
advanc
control
viral
pathogen
viral
infect
still
lack
specif
treatment
inde
need
effect
therapeut
strategi
combat
old
emerg
reemerg
virus
parallel
approv
new
antivir
past
year
drug
repurpos
combin
innov
approach
drug
valid
appropri
anim
model
significantli
contribut
identif
new
antivir
molecul
target
therapeut
intervent
review
describ
main
strategi
drug
repurpos
antivir
discoveri
discuss
promis
candid
could
repurpos
treat
viral
infect
analyz
possibl
caveat
trendi
strategi
drug
discoveri
highlight
identif
new
target
chemotherapeut
intervent
often
parallel
develop
licens
new
drug
antivir
agent
treat
viral
infecti
diseas
except
new
antivir
approv
food
drug
administr
fda
usa
treatment
hepat
c
viru
hcv
relat
patholog
combin
antihuman
immunodefici
viru
hiv
drug
wwwfdagov
hand
govern
world
health
organ
deal
critic
emerg
virus
character
pandem
potenti
respons
alarm
outbreak
recent
year
still
lack
specif
treatment
zika
viru
zikv
ebola
viru
ebov
middl
east
respiratori
syndrom
coronaviru
merscov
drug
discoveri
approach
recent
becom
popular
drug
repurpos
dr
consist
give
old
drug
new
indic
explor
new
molecular
pathway
target
intervent
dr
appli
viral
infecti
diseas
take
account
differ
strategi
integr
screen
bioactiv
smallmolecul
collect
comput
method
silico
screen
mine
databas
transcriptom
profil
etc
order
find
molecul
pathway
biolog
activ
could
recycl
fight
viral
pathogen
beyond
unquestion
econom
advantag
deriv
approach
drug
develop
process
repurpos
drug
quickli
enter
clinic
trial
employ
compassion
use
especi
case
viral
diseas
lack
specif
treatment
moreov
dr
repres
constant
sourc
new
knowledg
viru
biolog
well
molecul
previous
undescrib
antivir
properti
use
molecular
tool
uncov
molecular
mechan
viru
replic
pathogenesi
mani
case
dr
point
previous
unexplor
cellular
pathway
turn
target
new
therapeut
strategi
even
identifi
molecul
introduc
clinic
therapi
review
describ
meaning
result
bed
bench
approach
discuss
promis
drug
could
repurpos
treat
viral
infect
analyz
possibl
caveat
trendi
strategi
drug
discoveri
whose
advantag
pitfal
summar
tabl
repurpos
exist
drug
emerg
strategi
expedit
approv
effect
safe
therapeut
treatment
orphan
drug
diseas
new
indic
antivir
activ
identifi
molecul
differ
origin
show
repurpos
potenti
act
previous
known
target
new
antivir
target
innov
approach
target
valid
eg
gene
edit
crispr
new
experiment
model
eg
organoid
allow
identif
novel
antivir
agent
unravel
molecular
pathway
underli
viral
pathogenesi
drug
repurpos
success
identifi
promis
candid
drug
open
new
therapeut
avenu
counteract
current
viral
pathogen
possibl
emerg
virus
three
differ
scenario
antivir
dr
identifi
depend
whether
repurpos
molecul
previous
known
antivir
activ
figur
key
figur
targetnew
viru
first
option
antivir
drug
known
target
specif
viral
cellular
functionpathway
found
possess
activ
virus
antivir
activ
reli
structur
homolog
common
enzymat
featur
viral
target
share
pathway
exploit
viru
replic
viral
rna
polymeras
inhibitor
favipiravir
sofosbuvir
approv
treatment
influenza
viru
hcv
infect
respect
show
repurpos
potenti
ebov
zikv
see
anoth
exampl
repres
drug
eg
chloroquin
interfer
latestag
entri
process
virus
filovirus
coronavirus
exploit
cellular
endocyt
pathway
enter
host
cell
ii
targetnew
indic
occur
pharmacolog
target
ie
protein
pathway
modul
approv
drug
found
essenti
pathogen
process
associ
viral
infect
case
approv
drug
exploit
also
antivir
therapeut
agent
new
indic
case
exemplifi
anticanc
drug
imatinib
inhibit
cellular
abelson
abl
kinas
found
also
activ
pathogen
coronavirus
iii
new
targetnew
indic
occur
approv
drug
establish
bioactiv
specif
pathway
mechan
found
new
molecular
target
ie
show
polypharmacolog
see
glossari
essenti
viru
replic
exampl
antimicrobi
agent
eg
teicoplanin
ivermectin
itraconazol
nitazoxanid
found
target
also
virusinfect
cell
whose
inhibit
detriment
effect
viral
replic
drug
repurpos
potenti
viral
diseas
identifi
mostli
screen
smallmolecul
librari
consist
drug
approv
development
compound
known
bioactiv
includ
compound
natur
origin
librari
avail
public
institut
commerci
howev
number
glossari
arboviru
arthropod
born
viru
viru
replic
arthropod
transmit
vertebr
includ
human
hematophag
vector
mainli
mosquito
fli
tick
human
anim
arthropod
therefor
reservoir
gene
edit
system
type
genet
engin
base
use
cluster
regularli
interspac
short
palindrom
repeat
crispr
nucleas
system
act
molecular
scissor
delet
insert
genet
materi
precis
locat
within
genom
singl
cell
live
organ
microcephali
medic
condit
due
congenit
defect
circumfer
newborn
head
abnorm
smaller
expect
consequ
smaller
brain
microcephal
babi
may
develop
properli
stop
grow
microcephali
caus
viral
infect
toxin
exposur
drug
alcohol
abus
pregnanc
organoid
threedimension
cell
cultur
simplifi
yet
repres
version
organ
resembl
microanatomi
celltyp
composit
abl
recapitul
repres
organ
function
cultur
system
obtain
vitro
one
cell
deriv
tissu
stem
cell
induc
pluripot
stem
cell
abl
selfrenew
differenti
multipl
organspecif
cell
type
sever
organ
structur
obtain
date
repres
essenti
physiolog
model
studi
biolog
pathogen
process
includ
viral
infect
polypharmacolog
describ
abil
approv
drug
pharmaceut
molecul
act
multipl
target
relat
toxic
sideeffect
molecul
repres
import
opportun
drug
repurpos
pseudoviru
noninfecti
recombin
viruslik
particl
resembl
envelop
capsid
specif
viru
constitut
compon
pseudovirus
may
may
contain
genet
materi
proprietari
inhousemad
collect
also
exist
often
consist
one
class
drug
eg
kinas
apoptosi
inhibitor
etc
use
target
deconvolut
tabl
list
drug
collect
wide
use
antivir
dr
past
year
partnership
public
privat
institut
strongli
encourag
govern
expedit
identif
new
candid
drug
particular
orphan
diseas
sever
pharmaceut
compani
open
proprietari
collect
collabor
program
academ
research
group
despit
restrict
number
avail
collect
fact
often
drug
present
variou
librari
sever
case
differ
outcom
viral
pathogen
obtain
possibl
explan
differ
experiment
setup
use
includ
differ
cell
type
viru
strain
dose
readout
method
convers
screen
differ
librari
drug
independ
identifi
case
eg
mer
possibl
strategi
drug
repurpos
antivir
drug
discoveri
figur
repurpos
exist
drug
candid
drug
bioactiv
molecul
differ
origin
pursu
three
main
strategi
molecul
previou
known
antivir
activ
efficaci
virus
hypothes
test
base
similar
target
depend
common
pathway
absenc
previous
identifi
antivir
activ
repurpos
molecul
either
act
target
show
polypharmacolog
interfer
differ
function
cellular
viral
latter
case
target
valid
avoid
skip
preclin
phase
clinic
studi
first
two
approach
follow
conceiv
howev
may
possibl
repurpos
molecul
show
polypharmacolog
test
efficaci
suitabl
anim
model
remain
essenti
step
cov
see
final
virtual
screen
chemic
structur
also
perform
find
new
potenti
antivir
drug
howev
approach
depend
upon
avail
structur
inform
priori
knowledg
target
usual
requir
dr
screen
aim
discoveri
new
antivir
drug
valid
target
screen
fact
expost
target
valid
even
identif
possibl
activ
molecul
identifi
thu
dr
screen
mainli
undertak
two
differ
experiment
approach
unknown
targetphenotyp
assay
ii
known
target
mechanismbas
assay
first
case
target
gener
unknown
phenotyp
assay
employ
identif
hit
compound
phenotyp
assay
base
readout
synonym
antivir
activ
easili
monitor
highthroughput
format
exampl
protect
infect
cell
monolay
virusinduc
cytopath
effect
detect
lateexpress
structur
viral
protein
envelop
protein
case
frequent
exploit
hit
identif
phenotyp
assay
next
step
identif
valid
target
protein
pathway
etc
sometim
deduc
mechan
action
identifi
hit
compound
valid
requir
demonstr
target
inde
essenti
viru
replic
andor
pathogenesi
subordin
demonstr
modul
lead
protect
viru
infect
inhibit
virusassoci
pathogen
effect
experiment
approach
antivir
target
valid
exemplifi
genet
knockdown
rna
interfer
gene
edit
system
mutat
analysi
use
pharmacolog
inhibitor
avail
evalu
cultur
cell
organoid
ex
vivo
experiment
model
well
anim
model
final
possibl
clinic
valid
patientderiv
sampl
data
also
perform
inde
routin
employ
drug
found
potenti
effect
treatment
viral
infect
possibl
posit
correl
drug
administr
target
patient
inhibit
viral
infect
retrospect
analyz
clinic
studi
bioactiv
compound
includ
fdaapprov
drug
candid
drug
detail
descript
librari
found
altern
mechanismbas
dr
screen
target
valid
mandatori
prior
screen
design
frequent
target
druggabl
viral
cellular
enzym
receptor
experiment
setup
mechanismbas
assay
specif
design
identifi
molecul
abl
interfer
particular
process
previous
identifi
essenti
product
viru
replic
involv
viral
pathogenesi
assay
base
specif
mechan
inhibit
transcript
factor
protect
apoptosi
interf
specif
activ
mechan
inhibit
viru
entri
popular
approach
dr
screen
cellfre
system
vitro
assay
purifi
protein
use
howev
cellular
assay
engin
cell
line
recombin
virus
andor
replicon
system
pseudovirus
prefer
inform
target
modul
obtain
directli
physiolog
environ
compound
identifi
mechanismbas
assay
dr
screen
zikv
ebov
dna
virus
describ
although
dr
screen
base
mechanismbas
assay
could
conveni
target
known
sometim
fals
posit
identifi
limit
possibl
toxic
hit
due
offtarget
effect
miss
antivir
compound
act
differ
mechan
antivir
activ
restrict
singl
process
establish
priori
follow
section
describ
recent
advanc
repurpos
exist
candid
drug
treat
infect
caus
rna
dna
virus
tabl
prioriti
given
drug
show
efficaci
clinic
trial
anim
model
investig
drug
exhibit
effect
concentr
compat
clinic
achiev
plasma
level
human
zikv
flavivirus
zikv
arboviru
recent
caus
larg
outbreak
latin
america
gener
zikv
caus
selflimit
diseas
howev
zikv
infect
also
associ
neurolog
disord
syndrom
other
sever
congenit
defect
newborn
microcephali
ophthalmolog
alter
infect
occur
pregnanc
viru
capabl
humantohuman
spread
vertic
transplacent
sexual
transmiss
possibl
zikv
pandem
particular
concern
global
public
health
neither
specif
antivir
treatment
vaccin
counteract
zikv
diffus
avail
date
dr
campaign
report
shortli
declar
zikv
public
health
emerg
earli
case
collect
fdaapprov
drug
bioactiv
molecul
randomli
screen
other
specif
class
compound
consid
base
previou
activ
flavivirus
molecular
pathway
relev
pathogenesi
particular
zikvinduc
neuropathogenesi
first
dr
studi
among
identifi
inhibitor
zikv
replic
immunosuppress
drug
mycophenol
acid
antibiot
daptomycin
promis
wide
use
pregnanc
treat
diseas
abil
cross
placenta
importantli
drug
effect
antizikv
concentr
fall
rang
achiev
human
thu
repres
promis
candid
clinic
trial
success
dr
screen
identifi
fdaapprov
antihelminth
drug
niclosamid
macrolid
azithromycin
approv
antibacteri
agent
potent
inhibitor
zikv
replic
differ
neural
cell
line
target
zikv
fetal
infect
niclosamid
azithromycin
wide
use
drug
also
administ
pregnanc
categori
b
activ
concentr
zikv
clinic
achiev
thu
although
studi
need
evalu
antivir
efficaci
vivo
also
repres
promis
candid
antizikv
repurpos
final
structurebas
silico
screen
follow
vitro
vivo
experiment
studi
led
identif
anoth
antibiot
novobiocin
fdaapprov
drug
includ
niclosamid
temoporfin
novel
inhibitor
zikv
act
target
proteas
anoth
studi
nanchangmycin
polyeth
bacteri
origin
block
zikv
infect
differ
cell
line
well
ex
vivo
midbrain
neuronglia
mix
cultur
embryon
mice
importantli
nanchangmycin
show
antivir
activ
also
virus
share
clathrindepend
entri
mechan
anoth
natur
compound
alkaloid
hippeastrin
hydrobromid
hh
recent
emerg
promis
inhibitor
zikv
replic
microcephalyrel
effect
antizikv
effect
hh
human
fetallik
forebrain
organoid
report
well
rescu
organoid
cell
virusinduc
death
importantli
treatment
zikvinfect
organoid
hh
result
size
thick
compar
uninfect
organoid
thu
suggest
potenti
inhibitori
effect
compound
virusinduc
microcephali
fetal
infect
final
hh
also
effect
mous
model
zikv
infect
even
ad
day
postinfect
thu
highlight
impress
therapeut
potenti
studi
report
repurpos
potenti
zikv
drug
approv
treatment
hcv
infect
ribavirin
sofosbuvir
worth
mention
although
conflict
result
efficaci
latter
report
discrep
may
due
differ
cell
line
anim
model
use
explain
molecular
level
moreov
deeper
investig
safeti
sofosbuvir
pregnanc
need
consid
antihcv
drug
candid
treatment
zikv
fetal
infect
moreov
sever
antimalari
drug
show
antizikv
activ
particular
chloroquin
effect
reduc
zikv
vertic
transmiss
infect
pregnant
mice
neuroprotect
coupl
drug
abl
block
directli
viru
replic
fetal
infect
could
abl
attenu
neurodegen
effect
zikv
brain
ophthalmolog
damag
deriv
viru
infect
optic
nerv
ocular
tissu
nmethyldaspart
receptor
antagonist
particular
memantin
approv
treatment
alzheim
diseas
promis
neuroprotect
drug
human
primari
neuron
mice
infect
zikv
mani
drug
repurpos
potenti
zikv
also
activ
flavivirus
suggest
conserv
pathway
could
explor
develop
broadspectrum
antiflaviviru
agent
case
mycophenol
acid
niclosamid
nanchangmycin
cloroquin
antimalari
drug
hand
independ
dr
screen
japanes
enceph
viru
jev
hcv
dengu
viru
denv
led
identif
antivir
activ
differ
fdaapprov
drug
particular
dopamin
receptor
antagonist
prochlorperazin
identifi
potent
inhibitor
hcv
denv
act
interf
viru
attach
entri
anoth
drug
antihcv
repurpos
potenti
antihistamin
chlorcyclizin
show
antivir
activ
infecti
assay
chimer
mous
model
date
howev
none
compound
yet
evalu
clinic
trial
ebola
viru
ebov
filoviru
respons
sever
outbreak
sinc
discoveri
late
last
one
alarm
due
size
spread
inde
caus
intern
health
emerg
sinc
accident
import
ebov
case
record
nonendem
geograph
area
usa
europ
ebov
caus
lethal
diseas
character
acut
hemorrhag
fever
high
fatal
rate
despit
eas
transmiss
specif
therapeut
avail
yet
worsen
high
level
biocontain
necessari
manipul
viru
consider
hamper
develop
antivir
drug
vaccin
context
dr
studi
prompt
last
outbreak
extens
review
ebov
provid
uniqu
exampl
dr
approach
appli
directli
clinic
trial
last
outbreak
sever
drug
evalu
infect
patient
clinic
trial
compassion
use
test
abil
protect
lethal
ebov
infect
includ
viral
rna
polymeras
inhibitor
favipiravir
approv
japan
treatment
influenza
viru
adenosin
analog
activ
highli
pathogen
coronavirus
amodiaquin
antimalari
drug
wide
use
africa
treatment
ebovinfect
patient
drug
associ
decreas
fatal
rate
compar
control
patient
howev
efficaci
remain
confirm
random
clinic
studi
preclin
dr
studi
also
perform
live
virus
pseudovirus
led
identif
seri
approv
drug
abl
confer
protect
lethal
ebov
infect
anim
model
howev
drug
test
human
yet
drug
exert
antivir
activ
block
ebov
entri
step
bias
fact
use
pseudovirus
allow
identif
compound
inhibit
viral
entri
promis
antiebov
activ
determin
select
estrogen
receptor
modul
cloremiphen
toremiphen
chloroquin
relat
antimalari
drug
sertralin
bepridil
teicoplanin
cation
amphiphil
drug
amiodaron
broadspectrum
rna
polymeras
inhibitor
final
frontier
dr
directli
test
combin
drug
shown
antivir
activ
although
concentr
clinic
reachabl
human
approv
regimen
gave
success
result
inde
target
drug
combin
approach
result
identif
two
set
threedrug
cocktail
ie
toremifenemefloquineposaconazol
toremifeneclarithromycinposaconazol
previous
identifi
dr
act
synergist
ebov
entryinhibit
assay
concentr
achiev
human
coronavirus
cov
rna
virus
respons
gastrointestin
respiratori
neurolog
diseas
anim
zoonot
infect
human
particular
import
establish
potenti
crossspeci
transmiss
domest
anim
act
intermedi
host
respons
infect
human
major
concern
cov
infect
signific
morbid
mortal
emerg
new
virus
compet
humantohuman
transmiss
potenti
domest
anim
adapt
difficulti
identifi
intermedi
host
sever
acut
respiratori
syndrom
cov
sarscov
highli
pathogen
cov
emerg
china
respons
pandem
infect
peopl
mortal
wwwcdcgov
merscov
emerg
spread
countri
far
character
mortal
rate
thu
cov
repres
huge
threat
public
health
scenario
search
effect
therapeut
strategi
prioriti
global
public
health
manag
prompt
merscov
outbreak
three
independ
studi
report
approach
dr
anticov
drug
discoveri
publish
approv
drug
test
mersand
sarscov
two
molecul
identifi
two
independ
screen
dopamin
receptor
antagonist
chlorpromazin
antimalari
drug
chloroquin
report
also
antiflaviviru
activ
two
drug
exhibit
antivir
activ
virus
rang
clinic
achiev
human
howev
progress
preclin
studi
dr
approach
also
allow
identif
abl
tyrosin
kinas
oncogen
pathway
essenti
entri
cov
inde
abl
kinas
inhibitor
imatinib
approv
oral
anticanc
agent
inhibit
replic
mersand
sarscov
prevent
fusion
viru
endosom
membran
import
exampl
dr
determin
identif
host
factor
requir
pathogen
replic
find
novel
target
antivir
intervent
hosttarget
anticov
drug
cyclophylin
inhibitor
cyclosporin
alispovir
latter
drug
antivir
activ
mersand
sarscov
cell
cultur
fail
show
protect
effect
mous
model
sarscov
infect
nonetheless
cyclophylin
inhibitor
deserv
investig
pan
anticov
activ
hiv
proteas
inhibitor
also
identifi
dr
screen
show
efficaci
combin
interferon
merscov
infect
cell
nonhuman
primat
model
current
combin
lopinavirritonavir
interferon
treatment
merscov
syndrom
clinic
evalu
influenza
viru
belong
famili
orthomyxovirida
human
pathogen
global
public
health
import
caus
season
pandem
zoonot
influenza
diseas
outbreak
pandem
zoonot
influenza
strain
particular
concern
high
potenti
transmiss
given
absenc
preexist
immun
human
popul
oppos
rna
virus
describ
far
review
current
antivir
treatment
option
influenza
infect
howev
adamantan
inhibitor
viral
ion
channel
neuraminidas
inhibitor
suffer
rapid
emerg
drugresist
viral
strain
side
effect
thu
limit
therapeut
efficaci
therefor
new
antiinfluenza
drug
develop
dr
campaign
identifi
drug
alreadi
approv
clinic
evalu
show
antiinfluenza
properti
bay
approv
intraven
aspirin
exert
antivir
activ
block
nfkb
pathway
activ
dapivirin
nonnucleosid
inhibitor
retrotranscriptas
naproxen
target
influenza
nucleoprotein
antibiot
clarithromycin
clarithromycin
naproxen
along
oseltamivir
threedrug
combinationhav
evalu
phase
clinic
trial
show
efficaci
treatment
sever
influenza
also
nalidix
acid
dorzolamid
identifi
silico
screen
specif
target
mutant
viral
neuraminidas
show
efficaci
oseltamivirresist
influenza
wildtyp
virus
perhap
advanc
exampl
dr
case
antiparasit
drug
nitazoxanid
safe
drug
use
treatment
giardia
cryptosporidium
spp
infect
current
repurpos
treatment
influenza
nitazoxanid
promis
antiinfluenza
drug
candid
interfer
matur
viral
hemagglutinin
posttransl
level
show
efficaci
differ
latestag
clinic
trial
moreov
broadspectrum
antivir
activ
demonstr
drug
abl
block
replic
differ
virus
rais
hope
possibl
futur
indic
antivir
dr
also
explor
search
new
antivir
strategi
direct
dna
virus
consid
emerg
viral
pathogen
respons
latent
lifelong
infect
caus
high
morbid
lifethreaten
atrisk
popul
human
cytomegaloviru
hcmv
bherpesviru
establish
persist
infect
reactiv
condit
immunosuppress
hcmv
one
best
character
exampl
host
adapt
abil
virus
subvert
complet
cellular
physiolog
process
infect
cell
context
differ
dr
campaign
identifi
sever
approv
investig
drug
antihcmv
mechan
differ
current
avail
drug
case
statin
cardiac
glycosid
antiparasit
drug
emetin
nitazoxanid
kinas
inhibitor
antihypertens
drug
manidipin
drug
pharmacolog
modul
host
protein
thu
although
specif
viral
target
exclud
antihcmv
activ
like
reli
interfer
host
pathway
intercept
viru
studi
need
identifi
precis
molecular
mechan
dr
campaign
also
perform
identifi
inhibitor
hepat
b
viru
hbv
calciumchannel
blocker
dopamin
receptor
antagonist
antifung
terbinafin
emerg
promis
inhibitor
hbv
rna
transcript
dna
synthesi
virustarget
drug
also
show
repurpos
potenti
case
hiv
integras
inhibitor
demonstr
broadspectrum
activ
differ
herpesvirus
inhibit
viral
terminas
hiv
proteas
inhibitor
lopinavirritonavir
clinic
evalu
potenti
treatment
human
papilloma
viru
hpv
relat
preinvas
cervic
malign
lack
specif
therapi
viral
infecti
diseas
remain
major
medic
need
develop
effect
therapeut
subordin
understand
molecular
mechan
underli
viru
replic
pathogenesi
well
virushost
interact
remain
puzzl
sever
known
viral
pathogen
also
repres
main
challeng
futur
emerg
virus
context
evalu
repurpos
potenti
exist
candid
drug
repres
effect
strategi
develop
readytous
antivir
agent
well
identif
new
pathway
target
intervent
activ
drug
identifi
dr
could
principl
skip
preclin
phase
safetytoler
clinic
trial
directli
enter
phase
clinic
trial
test
efficaci
even
though
strategi
alreadi
demonstr
feasibl
develop
new
anticanc
drug
antifung
drug
itraconazol
second
life
anticanc
drug
antivir
drug
discoveri
still
success
exampl
influenza
ebov
merscov
see
outstand
question
import
issu
relat
dr
summar
tabl
still
remain
address
particular
translat
aspect
approach
well
possibl
obstacl
pharmaceut
develop
drug
show
repurpos
potenti
main
obstacl
success
repurpos
reli
perhap
effect
concentr
requir
antivir
activ
often
higher
clinic
achiev
approv
regimen
reconsid
administr
protocol
order
reach
higher
plasma
level
conveni
would
mean
lose
one
advantag
dr
could
feasibl
due
toxic
issu
effect
solut
issu
seem
develop
combin
therapi
exploit
synerg
two
three
drug
differ
mechan
action
promis
result
direct
accomplish
ebov
influenza
could
obtain
virus
combin
therapi
overcom
issu
low
potenc
drug
identifi
drug
repurpos
gap
left
lack
effect
anim
model
recapitul
human
viral
diseas
virusassoci
pathogenesi
fill
dr
approach
antivir
drug
discoveri
translat
evalu
repurpos
drug
directli
phase
ii
clinic
trial
similar
occur
diseas
cancer
neurodegen
disord
dr
benefit
product
public
privat
partnership
aim
overcom
intellectu
properti
program
restrict
busi
issu
prepar
clinic
evalu
potenti
repurpos
drug
futur
outbreak
highli
pathogenicpandem
virus
ebov
zikv
respiratori
virus
could
inform
experi
acquir
dr
campaign
use
determin
contain
newli
emerg
virus
futur
besid
lower
toxic
obtain
decreas
dose
combin
drug
combin
therapi
also
advantag
reduc
resist
issu
still
caveat
act
synergist
lower
dose
drug
need
interfer
differ
mechan
action
antivir
combin
therapi
effect
drug
inhibit
earli
possibl
differ
viral
function
host
pathway
involv
viru
replic
reason
search
new
antivir
target
therapeut
intervent
differ
approach
still
remain
mandatori
address
dr
campaign
